Jason Callahan
YOU?
Author Swipe
View article: Astronomical Cardiology: A Search For Heartbeat Stars Using <a:math xmlns:a="http://www.w3.org/1998/Math/MathML"> <a:mtext mathvariant="italic">Gaia</a:mtext> </a:math> and <c:math xmlns:c="http://www.w3.org/1998/Math/MathML"> <c:mtext mathvariant="italic">TESS</c:mtext> </c:math>
Astronomical Cardiology: A Search For Heartbeat Stars Using Gaia and TESS Open
Heartbeat stars are a subclass of binary stars with short periods, high eccentricities, and phase-folded light curves that resemble an electrocardiogram. We start from the catalogs of spectroscopic binaries and use photometry to identi…
View article: Optimisation of low and ultra-low dose scanning protocols for ultra-extended field of view PET in a real-world clinical setting
Optimisation of low and ultra-low dose scanning protocols for ultra-extended field of view PET in a real-world clinical setting Open
True total-body and extended axial field-of-view (AFOV) PET/CT with 1m or more of body coverage are now commercially available and dramatically increase system sensitivity over conventional AFOV PET/CT. The Siemens Biograph Vision Quadra (…
View article: High Detection Rates for Prostate-specific Membrane Antigen–avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography
High Detection Rates for Prostate-specific Membrane Antigen–avid Prostate Cancer Recurrence at Low Prostate-specific Antigen levels on Extended Axial Field-of-view Positron Emission Tomography/Computed Tomography Open
We investigated a new PET/CT scanner (positron emission tomography/computed tomography) for detection of prostate cancer recurrence. This more sensitive scanner had a higher detection rate, particularly for patients with low PSA (prostate-…
View article: Total-Body PET/CT: Pros and Cons
Total-Body PET/CT: Pros and Cons Open
PET/CT devices with an axial field-of-view (FOV) of 1 m allow simultaneous imaging from the head to the upper thighs, the typical axial extent of many "whole-body" oncological studies acquired by moving a patient sequentially through a con…
View article: Optimisation of low and ultra-low dose scanning protocols for ultra-extended field of view PET in a real-world clinical setting
Optimisation of low and ultra-low dose scanning protocols for ultra-extended field of view PET in a real-world clinical setting Open
True total-body and extended axial field-of-view (AFOV) PET/CT with 1m or more of body coverage are now commercially available and dramatically increase system sensitivity over conventional AFOV PET/CT. The Siemens Biograph Vision Quadra (…
View article: EP08.02-20 A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC
EP08.02-20 A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC Open
View article: P1.28-05 Cessation of Marrow Proliferation on FLT-PET with Low RT doses during chemoRT for NSCLC Correlates with Lymphocyte Decline
P1.28-05 Cessation of Marrow Proliferation on FLT-PET with Low RT doses during chemoRT for NSCLC Correlates with Lymphocyte Decline Open
View article: Reducing Patient Care Delays in Radiation Oncology via Optimization of Insurance Pre-Authorization
Reducing Patient Care Delays in Radiation Oncology via Optimization of Insurance Pre-Authorization Open
View article: The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)
The relationship between tumour dosimetry, response, and overall survival in patients with unresectable Neuroendocrine Neoplasms (NEN) treated with 177Lu DOTATATE (LuTate) Open
Peptide Receptor Radionuclide Therapy (PRRT) delivers targeted radiation to Somatostatin Receptor (SSR) expressing Neuroendocrine Neoplasms (NEN). We sought to assess the predictive and prognostic implications of tumour dosimetry with resp…
View article: Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study Open
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We c…
View article: Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study Open
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We c…
View article: Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study Open
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
View article: Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study Open
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
View article: Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study Open
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
View article: Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study Open
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
View article: Mid-treatment adaptive planning during thoracic radiation using 68 Ventilation-Perfusion Positron emission tomography
Mid-treatment adaptive planning during thoracic radiation using 68 Ventilation-Perfusion Positron emission tomography Open
View article: ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with<sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol
ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with<sup>89</sup>Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol Open
Background ImmunoPET is a multicentre, single arm, phase 0–1 study that aims to establish if 89 Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials. Methods The phase 0 study recru…
View article: Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma
Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma Open
View article: Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study Open
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II mu…
View article: Quantitative assessment of ventilation-perfusion relationships with gallium-68 positron emission tomography/computed tomography imaging in lung cancer patients
Quantitative assessment of ventilation-perfusion relationships with gallium-68 positron emission tomography/computed tomography imaging in lung cancer patients Open
View article: Predicting Malignancy in FDG-avid Thyroid Nodules based on Standardized Uptake Value in Oncology Patients
Predicting Malignancy in FDG-avid Thyroid Nodules based on Standardized Uptake Value in Oncology Patients Open
Aim and objective: Concomitant thyroid nodules and cancer found incidentally on 18-fluorodeoxyglucose (FDG) positron-emission tomography (PET-CT) in patients imaged for investigation or staging of malignancy have been progressively encount…
View article: FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma
FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma Open
View article: Automated assessment of functional lung imaging with 68Ga-ventilation/perfusion PET/CT using iterative histogram analysis
Automated assessment of functional lung imaging with 68Ga-ventilation/perfusion PET/CT using iterative histogram analysis Open
View article: The role of <sup>18</sup>F‐FDG PET/CT in retroperitoneal sarcomas—A multicenter retrospective study
The role of <sup>18</sup>F‐FDG PET/CT in retroperitoneal sarcomas—A multicenter retrospective study Open
Background The role of 18 F‐fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F‐FDG PET/CT) in the evaluation of retroperitoneal sarcomas is poorly defined. We evaluated the correlation of maximum standardized uptake…
View article: Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer
Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer Open
Background In the curative-intent treatment of locally advanced lung cancer, significant morbidity and mortality can result from thoracic radiation therapy. Symptomatic radiation pneumonitis occurs in one in three patients and can lead to …
View article: Suitability of PSMA-PET Biology-Guided Radiotherapy for Low Volume Metastases in Newly Diagnosed Prostate Cancer
Suitability of PSMA-PET Biology-Guided Radiotherapy for Low Volume Metastases in Newly Diagnosed Prostate Cancer Open
View article: Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma Open
Background Metastatic Merkel cell carcinoma (mMCC) is an aggressive neuroendocrine malignancy of the skin with a poor prognosis. Immune checkpoint inhibitors (ICIs) have shown substantial efficacy and favorable safety in clinical trials. M…
View article: Correlation of positron emission tomography ventilation-perfusion matching with CT densitometry in severe emphysema
Correlation of positron emission tomography ventilation-perfusion matching with CT densitometry in severe emphysema Open
Background Emphysema severity is frequently measured on CT via densitometry. Correlation with scintigraphic and spirometric functional measures of ventilation or perfusion varies widely, and no prior study has evaluated correlation between…
View article: CORRELATION OF POSITRON EMISSION TOMOGRAPHY PERFUSION-VENTILATION MATCHING WITH CT DENSITOMETRY IN SEVERE EMPHYSEMA.
CORRELATION OF POSITRON EMISSION TOMOGRAPHY PERFUSION-VENTILATION MATCHING WITH CT DENSITOMETRY IN SEVERE EMPHYSEMA. Open
View article: 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma Open